HemCon Medical Technologies, Inc. Announces Promising Results from Live Nail Infection Anti-Fungal Study Technology Platform Offers Tested Solution to Fungal Care Market

HemCon Medical Technologies, Inc. Announces Promising Results from Live Nail Infection Anti-Fungal Study Technology Platform Offers Tested Solution to Fungal Care Market

PORTLAND, Ore. – Feb. 5, 2009 – <!-- cpurl -->HemCon Medical Technologies<!-- /cpurl --> today announced preliminary data resulting from an independent, realistic study to treat and kill the T. Rubrum organism which causes Onychomycosis, a common fungal nail infection. The studies were conducted using a formulation based on HemCon’s newest proprietary platform technology available for license, Mycosinate™ (formerly known as A31S), that provides a controlled release broad spectrum antifungal and antibacterial agent to fight infection.

Independent testing of HemCon’s topical formulation, Mycosinate™ for the treatment of Onychomycosis was analyzed by <!-- cpurl -->MedPharm Ltd<!-- /cpurl -->.’s ChubTur® system using infected distal human nails. This system tests the ability to kill the T. Rubrum infecting the human nails over a period of time. HemCon’s formulation was evaluated against a placebo. In preliminary data, HemCon’s Mycosinate™ killed off the organism within a 14 day treatment plan. Additional testing to compare kill rates at three and seven day intervals will be completed by April 2009.

Fungal nail infections affect tens of millions of people worldwide and the market size for its treatment products is estimated at approximately US$4 billion. It is believed that 6-8 percent of all adults will acquire a fungal nail infection, and Onychomycosis is responsible for nearly 50 percent of reported cases.

“Our third, most accurate anti-fungal test yet, combined with earlier successes in nail penetration and human safety, affirms the exceptional promise of Mycosinate™ to provide effective relief for the millions of Americans afflicted with fungal nail infections,” said John W. Morgan, CEO of HemCon. “As HemCon continues to offer new technologies for commercialization that promote safe, effective healing, we pledge to work in tandem with our partners to offer patients solutions that improve lives on a global scale.”

About HemCon Medical Technologies Inc. HemCon Medical Technologies Inc., is a leading global developer of advanced medical products designed to improve the standard of patient care. The company is responsible for developing the chitosan-based HemCon dressing used by thousands of military and civilian first responders and is changing wound care best practices in hospital, dental and clinical settings. In addition, HemCon is leading the charge to develop and license unique, life-saving medical advances including Lyophilized Human Plasma and Nanospider™ technologies. HemCon is headquartered in Portland, Ore., with additional commercial operations in Ireland; England; Germany and the Czech Republic. For more information, please visit www.hemcon..com\

# # #

Public Relations Contact: Nicole Elovitz HemCon Medical Technologies Inc. 503-245-0459 nicole@hemcon.com

Posted: February 2009

View comments

Hide
(web5)